Takamura S
Jpn J Antibiot. 1985 Dec;38(12):3704-10.
Fundamental and clinical studies on gynecological use of aztreonam (AZT), a new monobactam, were performed with following results. Following the intravenous administration of 1 g dose of AZT, the transfer of AZT to pelvic dead space exudate was good, in which the concentration of that was 14.9 micrograms/ml (2 hours), 15.3 micrograms/ml (3 hours) after injection. The transfer of AZT to serum of umbilical cord and amniotic fluid was excellent. In a clinical trial, AZT was given to 5 patients with obstetric and gynecological infections. The clinical efficacy was evaluated as excellent in 1 case and good in the other 4 cases. No adverse effects were observed in any of the patients treated with AZT.
对新型单环β-内酰胺类药物氨曲南（AZT）用于妇科进行了基础和临床研究，结果如下。静脉注射1g剂量的氨曲南后，其向盆腔死腔渗出液的转运良好，注射后2小时该渗出液中氨曲南浓度为14.9微克/毫升，3小时时为15.3微克/毫升。氨曲南向脐带血清和羊水的转运良好。在一项临床试验中，对5例妇产科感染患者给予氨曲南治疗。临床疗效评估为1例优，4例良。接受氨曲南治疗的患者均未观察到不良反应。
